C WorldWide Group Holding A S decreased its holdings in shares of Coherus Biosciences Inc (NASDAQ:CHRS) by 16.4% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 199,854 shares of the biotechnology company’s stock after selling 39,117 shares during the quarter. C WorldWide Group Holding A S’s holdings in Coherus Biosciences were worth $1,759,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the stock. Wells Fargo & Company MN lifted its holdings in shares of Coherus Biosciences by 0.9% during the 2nd quarter. Wells Fargo & Company MN now owns 29,116 shares of the biotechnology company’s stock valued at $418,000 after acquiring an additional 253 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Coherus Biosciences by 12.6% during the 2nd quarter. Legal & General Group Plc now owns 9,341 shares of the biotechnology company’s stock valued at $134,000 after acquiring an additional 1,046 shares in the last quarter. California State Teachers Retirement System lifted its holdings in shares of Coherus Biosciences by 2.3% during the 2nd quarter. California State Teachers Retirement System now owns 67,940 shares of the biotechnology company’s stock valued at $975,000 after acquiring an additional 1,500 shares in the last quarter. Cornerstone Capital Management Holdings LLC. lifted its holdings in shares of Coherus Biosciences by 14.6% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 23,362 shares of the biotechnology company’s stock valued at $334,000 after acquiring an additional 2,979 shares in the last quarter. Finally, Voya Investment Management LLC lifted its holdings in shares of Coherus Biosciences by 32.2% during the 2nd quarter. Voya Investment Management LLC now owns 17,607 shares of the biotechnology company’s stock valued at $253,000 after acquiring an additional 4,293 shares in the last quarter. Institutional investors and hedge funds own 78.87% of the company’s stock.

CHRS has been the topic of several recent research reports. ValuEngine lowered shares of Coherus Biosciences from a “sell” rating to a “strong sell” rating in a report on Thursday, October 26th. Citigroup restated a “buy” rating and set a $23.00 target price on shares of Coherus Biosciences in a report on Tuesday, November 7th. BidaskClub upgraded shares of Coherus Biosciences from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Finally, Zacks Investment Research upgraded shares of Coherus Biosciences from a “hold” rating to a “buy” rating and set a $11.00 target price on the stock in a report on Wednesday, January 3rd. Two analysts have rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $29.67.

Shares of Coherus Biosciences Inc (NASDAQ CHRS) opened at $9.45 on Friday. Coherus Biosciences Inc has a one year low of $8.05 and a one year high of $26.55. The stock has a market cap of $562.50, a price-to-earnings ratio of -1.74 and a beta of 3.81. The company has a current ratio of 5.46, a quick ratio of 5.46 and a debt-to-equity ratio of 1.84.

ILLEGAL ACTIVITY NOTICE: “C WorldWide Group Holding A S Sells 39,117 Shares of Coherus Biosciences Inc (CHRS)” was first posted by Daily Political and is the property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and reposted in violation of international copyright and trademark legislation. The original version of this story can be viewed at https://www.dailypolitical.com/2018/02/11/c-worldwide-group-holding-a-s-sells-39117-shares-of-coherus-biosciences-inc-chrs.html.

Coherus Biosciences Company Profile

Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.

Want to see what other hedge funds are holding CHRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Coherus Biosciences Inc (NASDAQ:CHRS).

Institutional Ownership by Quarter for Coherus Biosciences (NASDAQ:CHRS)

Receive News & Ratings for Coherus Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.